SUBSCRIBE
SUBSCRIBE
News   Business

Evotec AG Reports Good Progress in Product Development in Treatment-Resistant Depression in its Alliance With Roche

March 10, 2010 | 
1 min read
HAMBURG, Germany, March 10, 2010 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt:EVT) (TecDAX) today announced two positive aspects that strengthen its integrated product development in treatment-resistant depression in its strategic alliance with Roche.
Alliances Clinical research Phase 1 Europe
Roche
MORE ON THIS TOPIC
3D. rocket soaring. Different rockets fly high and stand out. different from others, concept startup idea, new generation, faster work better
Drug Development
Is Revolution ‘the next oncology titan’? Truist analysts make the case
May 18, 2026
 · 
3 min read
 · 
Heather McKenzie
Fashionable halftone collage. Concept of partnership, sponsorship,agreement, contract conclusion. Illustration for web banner, social media banner, business presentation, marketing material. Vector illustration
Deals
Regeneron, Parabilis set out to create new drug class in deal worth up to $2.3B
May 18, 2026
 · 
2 min read
 · 
Gabrielle Masson
Human liver organ and pills. World hepatitis day. National liver health awareness month. Liver transplantation, donation background. Save patient life in hospital with liver transplant
Postmarket research
Amgen’s rare disease drug Tavneos tied to 20 deaths in Japan
May 18, 2026
 · 
2 min read
 · 
Tristan Manalac
Target, miss the target, target shooting, dart, correct decisions, bow and arrow, dart on target, hits and misses (3d illustration)
Cancer
Regeneron misses again as melanoma combo bows to Merck’s Keytruda in Phase 3
May 18, 2026
 · 
2 min read
 · 
Tristan Manalac